Arjun Law
YOU?
Author Swipe
View article: Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering
Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering Open
The utilization of eltrombopag (EPAG) in the management of post allogenic hematopoietic cell transplant (HCT) cytopenia has exhibited promising outcomes. Isolated thrombocytopenia and poor graft function (PGF) are factors that adversely in…
View article: Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)
Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS) Open
Introduction Post-transplant surveillance using measurable residual disease (MRD) and donor chimerism provides critical information to assess relapse risk and graft stability in acute myeloid leukemia (AML) or myelodysplastic syndromes (MD…
View article: Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study
Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study Open
Background The optimal in-vivo T-cell depleting agent for allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemia (SAA) remains unclear. Current guidelines endorse the use of either rabbit anti-thymocyt…
View article: Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival Open
Chronic graft-versus-host disease (cGvHD) remains one of the common causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Belumosudil (BEL), a selective ROCK2 inhibitor, has immunomodulatory and anti-f…
View article: Can we move beyond myeloablative conditioning ( <scp>MAC</scp> )? A comparison of <scp>MAC</scp> versus reduced intensity conditioning ( <scp>RIC</scp> ) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using <scp>ATG</scp> ‐ <scp>PTCy</scp> ‐ <scp>CSA</scp> for <scp>GVHD</scp> prophylaxis
Can we move beyond myeloablative conditioning ( <span>MAC</span> )? A comparison of <span>MAC</span> versus reduced intensity conditioning ( <span>RIC</span> ) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using <span>ATG</span> ‐ <span>PTCy</span> ‐ <span>CSA</span> for <span>GVHD</span> prophylaxis Open
Summary Allogeneic haematopoietic cell transplantation (HCT) offers a curative option for numerous haematological disorders; however, its myeloablative conditioning (MAC) regimens are associated with substantial toxicity. Reduced intensity…
View article: Endothelial activation and stress index ( <scp>EASIX</scp> ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment
Endothelial activation and stress index ( <span>EASIX</span> ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment Open
Summary Steroid‐refractory acute graft‐versus‐host disease (SR‐aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR‐aGvHD, failure predictors are poorly d…
View article: HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative
HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative Open
INTRODUCTION: This collaborative study aims to present the results obtained from the implementation of the Hematopoietic Cell Transplantation Frailty Scale (HCT-FS) for the assessment of frailty in adult candidates for allogeneic hematopoi…
View article: Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation
Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation Open
Summary Second primary malignancies (SPMs) are a well‐recognized late complication of allogeneic haematopoietic stem cell transplantation (HSCT). This study aims to evaluate the impact of anti‐thymocyte globulin (ATG) and post‐transplant c…
View article: Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte‐colony Stimulating Factor Administration: A Case Report
Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte‐colony Stimulating Factor Administration: A Case Report Open
Granulocyte‐colony stimulating factor (G‐CSF) is routinely used for peripheral blood stem cells (PBSC) mobilization in healthy donors for allogeneic hematopoietic stem cell transplantation, with mild, transient adverse effects. Pulmonary c…
View article: Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based <scp>GVHD</scp> Prophylaxis
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based <span>GVHD</span> Prophylaxis Open
Introduction Myeloablative conditioning (MAC) for acute myeloid leukemia (AML) improves disease control by reducing relapse risk but is associated with higher non‐relapse mortality (NRM). Reduced‐intensity conditioning (RIC) aims to minimi…
View article: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms Open
Myelodysplastic/myeloproliferative overlap neoplasms (MDS/MPN) are rare hematological malignancies. We analyzed the outcomes of 75 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for MDS/MPN. Graft‐versus‐host…
View article: Exploring Outcomes by Ethnicity in Allogeneic Hematopoietic Cell Transplantation
Exploring Outcomes by Ethnicity in Allogeneic Hematopoietic Cell Transplantation Open
Background: Clinical outcome disparities among racial and ethnic groups have been described following allogeneic hematopoietic cell transplantation (HCT). This study investigated the impact of race and ethnicity on HCT outcomes in a multi-…
View article: Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD
Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD Open
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) …
View article: Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference? Open
Background. Despite decades of post–allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been cha…
View article: PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation Open
Posttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) tr…
View article: Both Pre- and Post-Allogeneic Stem Cell Transplant Ferritin Are Associated with Relapse: A Large Single Centre Retrospective Study
Both Pre- and Post-Allogeneic Stem Cell Transplant Ferritin Are Associated with Relapse: A Large Single Centre Retrospective Study Open
Introduction: Allogeneic hematopoietic cell transplantation (AlloHSCT) is a curative treatment for numerous hematological disorders. Transfusional iron overload continues to be a challenging complication in spite of advances in supportive …
View article: The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes Open
Introduction: Allogeneic hematopoietic cell transplantation (Allo-HCT) is the curative treatment for various hematological disorders. Despite advancements in supportive care, graft-versus-host disease (GVHD) continues to be a challenging c…
View article: Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease Open
Introduction: Contemporary practice for frontline chronic graft-versus-host disease (cGvHD) treatment predominantly involves the use of systemic corticosteroids. Treatment with newer agents for cGvHD including ruxolitinib, belumosudil or a…
View article: Strength to Endure: Superiority of MAC over RIC in Patients &lt;65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis Open
Background: Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) is a curative treatment for many hematological diseases. Reduced-intensity conditioning (RIC) regimens were developed to decrease the toxicities associated with myeloabla…
View article: The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation
The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation Open
Post transplant cyclophosphamide (PTCY) has broadened the access to allogeneic stem cell transplantation. However, it is also associated with increased organ toxicity and infections in these patients. We intended to determine whether the o…
View article: Improved Outcomes with Myeloablative Conditioning in AML Patients below 65 Years Using a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide As Gvhd Prophylaxis
Improved Outcomes with Myeloablative Conditioning in AML Patients below 65 Years Using a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide As Gvhd Prophylaxis Open
Background: Allogeneic hematopoietic cell transplantation (Allo-HCT) is a critical treatment option for achieving long-term remission in patients with acute myeloid leukemia (AML), particularly those with intermediate or high-risk disease.…
View article: Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis Open
Background: Monocytopenia has been associated with inferior survival following allogeneic hematopoietic stem cell transplantation (allo-HCT). Post-transplantation cyclophosphamide (PTCy) for graft versus host disease (GVHD) prophylaxis has…
View article: Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis Open
Introduction: Post-transplant cyclophosphamide (PTCy) is a safe and effective graft versus host disease (GVHD) prophylaxis strategy. While initially established as the standard of care for haploidentical allogeneic hematopoietic cell trans…
View article: Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation
Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation Open
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO‐incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti‐donor isohemagglutini…
View article: Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML Open
PURPOSE Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate …